Title
A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants
Recommended Citation
Rodriguez NA, Moya F, Landino J, et al. A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants [published online ahead of print, 2023 Jan 3]. J Perinatol. 2023;10.1038/s41372-022-01589-x. doi:10.1038/s41372-022-01589-x
Abstract
Objective: To determine if oropharyngeal therapy with mother's own milk (OPT-MOM) reduces late-onset sepsis (L-OS; primary outcome), NEC, death, length of stay, time to full enteral nutrition (FEN) and full oral feeds in preterm infants (BW < 1250 g).
Design: Infants (N = 220) were randomized to Group A (milk) or B (placebo) and received 0.2 mL every 2 h for 48 h, then every 3 h until 32 weeks CGA.
Results: There were no significant differences in L-OS, NEC or death. Group A trended towards an 8-day reduction in stay, 8-day reduction in time to FEN and a 6-day reduction in time to full oral feeds, compared to B. While clinically relevant, due to large variability in outcomes and lack of power, p values were > 0.05.
Conclusion: OPT-MOM did not reduce L-OS, NEC or death. Group A trended towards a reduced stay and better nutritional outcomes, but results were not statistically significant.
Clinicaltrials: GOV: NCT02116699 .
Erratum in
- Correction to: A randomized controlled trial of oropharyngeal therapy with mother's own milk for premature infants. Rodriguez NA, Moya F, Ladino J, Zauk A, Prazad P, Perez J, Vento M, Claud E, Wang CH, Caplan MS. J Perinatol. 2023 Jan 16. doi: 10.1038/s41372-023-01607-6. Online ahead of print. PMID: 36646823 No abstract available.
Document Type
Article
PubMed ID
36596945
Affiliations
Advocate Children's Hospital-Park Ridge